In US sometime it’s the investor’s who turn around the game for fate of the firm in a given industry, In Pharma from the days of its inception there is lot strong lobby going on which have lead to many decisions in favor of the republican lead lobby such as Biotech drug exclusivity and NDA exclusivity. In India like the Gilead and Pfizer, Eli lilly, Abbott of the world we have Cipla which has replicated the trends in the democracy.
Yesterday I was reading about the article that current CEO of Eli lilly who is veteran for 32 years went against the stake holders opinion of cutting down on R&D budgets , what we have observed over the last decade is that Eli lilly had around 8 blockbuster molecules in its pipeline
Eli lilly pipeline: One of the Top ten research based companies in the world in terms of sales with block buster products sales exceeding US $1 Billion
Lilly has around compounds Byetta, Cialis, Alimta, and Cymbalta all of which are strong entries to their respective markets. Overall sales is going to rise steadily as mentioned in Epsicom report.
Sales of Major Products (2003A-2013E)
So I second the CEO’s opinion in aspect of allotment of resource for R&D development but also to focus on more licensing deals and mergers and acquisitions in some broad area such as rare diseases and increase in sales in emerging markets
Link: http://www.fiercebiotech.com/story/lilly-outlines-turnaround-strategy-ceo-calls-research-cuts-nuts/2011-06-30
No comments:
Post a Comment